Key Takeaways
- •Melasma is a chronic pigmentation disorder driven by hormones, UV exposure, and heat — not just sun damage.
- •It affects up to 50 million people worldwide, predominantly women with darker skin tones.
- •Hydroquinone remains the gold standard topical treatment, but it must be used carefully and cyclically.
- •Sunscreen alone is not enough — visible light and heat also trigger melasma.
- •Treatment is about management, not cure — melasma is a chronic condition that requires ongoing maintenance.
- •Triple combination therapy (hydroquinone + tretinoin + steroid) is the most effective topical approach.
What Melasma Actually Is
Melasma is a chronic acquired pigmentation disorder characterized by symmetrical brown or grayish-brown patches, most commonly appearing on the cheeks, forehead, upper lip, nose, and chin. Unlike post-inflammatory hyperpigmentation (PIH), which follows an injury or inflammation, melasma develops in the absence of any preceding skin damage. It's driven by a complex interplay of hormonal, environmental, and genetic factors.
The condition affects an estimated 1.5–33% of the population depending on demographics, with significantly higher prevalence in women (90% of cases) and individuals with Fitzpatrick skin types III–V. The name comes from the Greek word 'melas' meaning dark, and the condition has been recognized for centuries, though our understanding of its pathophysiology has advanced considerably in recent decades.
What makes melasma uniquely frustrating is its chronic, relapsing nature. Unlike a dark spot from a pimple that will eventually fade, melasma is a condition you manage rather than cure. The melanocytes in melasma-affected skin are fundamentally hyperactive — they're not just producing excess melanin in response to a one-time trigger, they're perpetually primed to overproduce pigment.
The Triggers Behind Melasma
Hormonal influences are the most significant trigger for melasma, which is why it's sometimes called the 'mask of pregnancy.' Estrogen and progesterone stimulate melanocyte activity, and melasma frequently appears or worsens during pregnancy, with oral contraceptive use, or during hormone replacement therapy. Studies have shown that melanocytes in melasma-affected skin have increased estrogen receptors compared to normal skin.
Ultraviolet radiation is the most important environmental trigger. UV exposure stimulates melanocyte-stimulating hormone (MSH) and other mediators that drive melanin production. But UV isn't the only light-based trigger — visible light (particularly blue light from screens and indoor lighting) and infrared radiation (heat) have been shown to stimulate melanogenesis in darker skin types. This is why some melasma patients worsen despite diligent sunscreen use.
Genetic predisposition plays a significant role. Research has identified multiple gene variants associated with melasma susceptibility, and the condition has a strong familial tendency. If your mother or sisters have melasma, your risk is substantially higher. Other contributing factors include thyroid disorders, stress, and certain medications that increase photosensitivity.
Why Standard Dark Spot Treatments Often Fail
Many people with melasma initially approach it as they would any other form of hyperpigmentation — with brightening serums and exfoliating acids. While these can provide modest improvement, they fundamentally misunderstand the nature of melasma. Standard PIH treatments target excess melanin that's already been deposited, but melasma involves chronically overactive melanocytes that keep producing new pigment.
Additionally, many melasma cases involve both epidermal and dermal pigment deposition. Epidermal melasma (brown patches) is more responsive to topical treatment because the pigment is in the upper layers of skin. Dermal melasma (grayish-blue patches) has melanin trapped in dermal macrophages, making it far more resistant to topical intervention. Mixed melasma — the most common presentation — has components of both.
Aggressive treatments like deep chemical peels, ablative lasers, and intense pulsed light (IPL) can actually worsen melasma by triggering rebound hyperpigmentation. The inflammation from these procedures stimulates the already hyperactive melanocytes to produce even more pigment. This paradoxical worsening is one of the most common treatment pitfalls and why melasma requires a gentle, sustained approach rather than aggressive intervention.
Evidence-Based Treatment Approaches
The gold standard topical treatment for melasma is triple combination therapy — a prescription cream containing hydroquinone (4%), tretinoin (0.05%), and a mild corticosteroid (fluocinolone acetonide 0.01%). This combination, often referred to by the brand name Tri-Luma, addresses melasma through three mechanisms: tyrosinase inhibition (hydroquinone), increased epidermal turnover (tretinoin), and anti-inflammatory action (corticosteroid). Clinical trials show it's more effective than any single agent alone.
For maintenance and over-the-counter management, SkinCeuticals Discoloration Defense combines tranexamic acid, niacinamide, and kojic acid in a formulation specifically designed for pigmentation disorders. Tranexamic acid is emerging as a particularly promising treatment for melasma — both topical and oral forms have shown significant efficacy in clinical trials, with a mechanism that interrupts the UV-stimulated melanogenic pathway.
Sunscreen is non-negotiable, but standard chemical sunscreens may not be sufficient. EltaMD UV Clear Broad-Spectrum SPF 46 provides broad-spectrum protection with zinc oxide and is formulated for sensitive, pigmentation-prone skin. However, because visible light also triggers melasma, tinted sunscreens containing iron oxide provide superior protection by blocking both UV and visible light wavelengths. La Roche-Posay Mela-D Pigment Control combines glycolic acid with kojic acid for daily brightening support alongside your sunscreen. Some dermatologists are exploring the use of red light therapy as a complementary approach to managing melasma alongside topical treatments, particularly for its anti-inflammatory properties.
The Role of Oral Treatments
Oral tranexamic acid has generated significant excitement in the melasma treatment space. Originally developed as an antifibrinolytic medication to control bleeding, tranexamic acid has shown remarkable efficacy against melasma at low doses (250mg twice daily). A landmark randomized controlled trial published in the Journal of the American Academy of Dermatology found that oral tranexamic acid significantly reduced melasma severity scores compared to placebo.
The mechanism is thought to involve inhibition of plasminogen activator in keratinocytes, which reduces the production of prostaglandins and arachidonic acid — both of which stimulate melanocyte activity. Because it works systemically, oral tranexamic acid can reach dermal melanocytes that topical treatments cannot. However, it does carry a small risk of thromboembolic events and should only be used under medical supervision with appropriate screening.
Other oral agents under investigation include polypodium leucotomos extract, a fern-derived antioxidant that has shown photoprotective properties in clinical trials, and glutathione, an endogenous antioxidant that may shift melanin production from darker eumelanin toward lighter pheomelanin. While neither has the robust evidence base of tranexamic acid, they represent promising adjunctive options.
In-Office Procedures for Melasma
Gentle chemical peels — particularly superficial glycolic acid or modified Jessner's peels — can be effective when used as part of a comprehensive melasma treatment plan. The key is superficial depth; deeper peels risk inflammatory hyperpigmentation. Serial superficial peels every 2–4 weeks, combined with topical therapy, produce better outcomes than either approach alone.
Low-fluence Q-switched Nd:YAG laser (laser toning) has shown promise for melasma, particularly the dermal component. This technique uses multiple passes at low energy settings to gradually break down melanin without causing the inflammation that triggers rebound pigmentation. However, results are variable, and some patients experience post-treatment worsening. Patient selection and practitioner expertise are critical.
Microneedling, either alone or as a drug delivery system for tranexamic acid or vitamin C, is another option being explored. The controlled micro-injury creates channels that allow topical agents to penetrate more deeply, potentially reaching dermal pigment. Early studies are encouraging but the evidence base is still developing compared to established treatments.
Long-Term Management and Prevention
The most important concept in melasma management is that it's a chronic condition requiring ongoing maintenance. Even after successful clearing, melasma will recur if protective measures are abandoned. Lifelong sunscreen use is the single most important preventive measure — broad-spectrum SPF 30+ with iron oxide, applied daily and reapplied every two hours during sun exposure.
Maintenance therapy with non-hydroquinone agents like azelaic acid (15–20%), vitamin C, niacinamide, or tranexamic acid can help prevent recurrence without the risks associated with long-term hydroquinone use. Cycling topical treatments — for example, using hydroquinone for 3–4 months followed by a non-hydroquinone brightening agent — is a common approach to maximize efficacy while minimizing side effects.
Beyond skincare, lifestyle modifications matter. Heat is a significant trigger, so activities that substantially raise facial temperature — hot yoga, saunas, cooking over a hot stove — can worsen melasma. Wide-brimmed hats provide additional physical photoprotection. For women whose melasma is hormonally driven, discussing contraceptive options with their gynecologist may be worthwhile, as progesterone-only methods may be less likely to exacerbate the condition.
References
- Ogbechie-Godec OA, Elbuluk N. "Melasma: an up-to-date comprehensive review." Dermatology and Therapy. 2017;7(3):305-318.
- Sarkar R, et al. "Melasma in men: a review of clinical, etiological, and management issues." Journal of Clinical and Aesthetic Dermatology. 2020;13(4):23-27.
- Del Rosario E, et al. "Randomized, placebo-controlled, double-blind trial of oral tranexamic acid in the treatment of moderate-to-severe melasma." Journal of the American Academy of Dermatology. 2018;78(2):363-369.
- Passeron T, Picardo M. "Melasma, a photoaging disorder." Pigment Cell & Melanoma Research. 2018;31(4):461-465.
